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tively). The SHRSP group had 12-fold higher levels of total aortic reactive oxygen species
(ROS) assessed by 8-iso-PGF2α, and 4-fold increase in superoxide content assessed by
hydroethidine staining of the aortic media. Both drugs significantly reduced ROS and
NAD(P)H oxidase essential subunit p22phox and its activity (P<0.05), whereas p-Akt,
eNOS, and the contractile-type smooth muscle myosin heavy chain SM2 were signifi-
cantly increased in SHRSP aorta (P<0.01). In addition, E4177 was more effective at
inducing VSMC differentiation by a 43% reduction of ROS through the downregulation of
NAD(P)H oxidase activity, and the upregulation of p-Akt by 27%, eNOS by 32%, and
SM2 by 34% compared with cilazapril respectively (P<0.05). Conclusions- An ACE
inhibitor and an AT1 receptor antagonist inhibited VSMC dedifferentiation through the
reduction of ROS by inhibiting NAD(P)H oxidase, and the upregulation of eNOS and Akt
in SHRSP aorta; suggesting that, in contrast to the results from in vitro experiments,
eNOS and Akt activation through the inhibition of AT1 receptor might be crucial determi-
nants for VSMC differentiation in hypertension in vivo.
1161-173 Stromelysin-1 (MMP-3) Gene 5A/6A Promoter 
Polymorphism Is Associated With Blood Pressure in a 
Community Population
John Beilby, Joseph Hung, Caroline Chapman, Brendan McQuillan, Peter Thompson, Sir 
Charles Gairdner Hospital, Perth, Australia, PathCentre QEII Medical Center, Perth, 
Australia
Background: Vascular remodelling of large and small arteries contributes to the devel-
opment of hypertension. Stromelysin-1, a member of the matrix metalloproteinase
(MMP) family may contribute to arterial remodelling. The expression of stromelysin-1
gene is partly regulated by a common polymorphism in the promoter region of either five
or six consecutive adenosine bases (5A/6A) that alter transcription factor binding.
Methods: A cross-sectional study of 1,111 randomly selected community subjects (553
males and 558 females), age 27-77 years, who were assessed for conventional cardio-
vascular risk factors and the stromelysin-1 5A-1171/6A genotype. Mean common carotid
intima-medial wall thickness (IMT) and presence of plaque was determined by carotid
ultrasound.
Results: The frequency of the stromelysin-1 -1171/5A allele was 0.45. Univariate analy-
sis demonstrated an association between the stromelysin-1 5A-1171/6A genotype and
blood pressure in the whole population. Multivariate analysis showed an independent
association between the stromelysin-1 genotype and systolic and diastolic blood pres-
sure (both P<0.005) in the whole sample. When the population was split by smoking sta-
tus, an independent association with systolic blood pressure (P<0.0001) and diastolic
blood pressure (P=0.006) was present only in smokers. Subjects who smoked and car-
ried the 5A/5A genotype had a higher mean systolic (+6.0 mmHg) and diastolic (+2.5
mmHg) blood pressure compared to 5A/6A and 6A/6A carriers. The association between
the stromelysin-1 genotypes and blood pressure was recessive with the effect only seen
with the 5A/5A genotype. Multivariate analysis in the whole population showed there was
no association with mean IMT (P=0.42) or the likelihood of carotid plaque formation
(P=0.08).
Conclusions: In this large randomly selected, cross-sectional population, the 5A/5A
variant in the stromelysin-1 gene promoter was independently associated with increased
blood pressure in the whole population and in smokers but was not associated with either
increased carotid IMT or plaque formation.
1161-174 Pulse Pressure and Interactions Between 
Polymorphisms in the Angiotensin II Type 1 Receptor 
and Uncoupling Protein 1 Genes in Hypertensive Hong 
Kong Chinese
Yu-Jing Fang, Cai-Xia Li, Ji-Qian Fang, G Neil Thomas, Brian Tomlinson, Chinese 
University of Hong Kong, Hong Kong, People's Republic of China, Sun Yat-Sen 
University, Guangzhou, People's Republic of China
Background: Hypertension and obesity are strongly inter-related and have multifactorial
genetic and environmental components. The angiotensin II type 1 receptor (AT1R) is
involved in the regulation of blood pressure and polymorphisms in this gene have been
implicated in the development of hypertension. The uncoupling protein 1 (UCP1) is solely
expressed in brown adipose tissue and genetic polymorphisms affecting this may be
associated with obesity. The present study was performed to assess the contribution of
polymorphisms of these two genes on blood pressure or obesity parameters in a family
study.
Methods: We studied members of 96 families with a hypertensive proband, including 282
siblings, of which 133 were hypertensive and 144 were obese. Blood pressure, pulse
pressure, body mass index (BMI) and waist:hip ratio (WHR) were recorded for each sib-
ling. The AT1R gene A1166C polymorphism and the UCP1 gene A-3826G polymorphism
were identified with polymerase chain reaction based RFLP protocols. A multi-level
mixed linear model for quantitative trait locus (QTL) analysis was applied to identify
whether these genetic polymorphism loci were related to blood pressure, pulse pressure
or body weight.
Results: No significant association was found between the AT1R and UCP1 gene poly-
morphisms and systolic or diastolic blood pressure. Age and the BMI/WHR ratio were
strongly related to the systolic blood pressure (p<0.0001), diastolic blood pressure
(p<0.0001) and pulse pressure (p=0.0003). Gender was only related to pulse pressure
(p=0.0003). For the AT1R and UCP1 gene polymorphisms, the QTL analysis showed that
the AT1R gene A1166C polymorphism was related to pulse pressure after adjustment for
age, gender and BMI/WHR ratio (p=0.038). A significant gene-gene interaction for pulse
pressure was found between the two gene polymorphisms after adjustment for age, gen-
der and BMI/WHR ratio (p=0.031).
Conclusions: Genetic variation at the AT1R gene locus may modify the risk for developing
abnormal pulse pressure. An interaction between the AT1R genotype and UCP1 geno-
type suggests these loci may be important in determining abnormal blood pressures in
relation to obesity.
1161-175 Platelet-Derived Vascular Endothelial Growth Factor in 
Patients With Hypertension: Relationship to Platelet 
Activation and Plasma Indices of Angiogenesis
Sunil K. Nadar, Graham J. Caine, Andrew D. Blann, Gregory YH Lip, City Hospital, 
Birmingham, United Kingdom
Aims: Platelet activation is an important part of the pathogenesis of complications in
hypertension (HT). Hypertension is also associated with abnormal angiogenesis. We
hypothesise a relationship of platelet derived Vascular Endothelial Growth Factor (VEGF)
to plasma markers of angiogenesis (VEGF, Angiopoietin (Ang)-1 and 2, and Ang receptor
Tie-2) and platelet activation (soluble P-selectin) in hypertension.
Methods: We studied 199 (151 male, mean age 67+ 9 years) patients with HT and 59
normotensive controls( 41 male; mean age 68+11 years). Plasma levels of angiogenesis
such as VEGF, Ang-1, and Ang2, and Tie-2 were determined by ELISA. Platelet derived
VEGF was measured by lysing a fixed number of platelets, and measuring the levels in
the lysate so obtained.
Results: Plasma indices were abnormal in HT versus controls [Table1]. Platelet derived
VEGF did not vary with the use of aspirin or antihypertensive agents. Platelet derived
VEGF correlated with plasma levels of VEGF( Spearmans r=0.257, p=0.001), Ang 1
(r=0.307, p=0.001) and Tie 2 (r=0.19 p=0.007), but not with soluble p-selectin.
Conclusions: Hypertensive patients have raised platelet derived VEGF which correlates
with the plasma levels of VEGF and Ang-1. This suggests a role for platelets in the abnor-
mal angiogenesis that is seen in hypertension
1161-176 Carvedilol Reduces Serum Concentration of DNA-
Damage Biomarker 8-Hydroxydeoxyguanosine in 
Human Hypertension
Juyong Lee, Mejeong Lee, Jung-Wook Kim, Jin-Geun Jang, Yoon-Suck Choi, Sang-Sig 
Cheong, Gangneung Asan Hospital, Gangneung-si, South Korea
Background: Oxidative DNA damage due to reactive oxygen species(ROS) has been
implicated in cardiovascular diseases. Deoxyguanosine is one of the constituents of DNA
and when it is oxidized, it is altered into 8-OHdG. The serum concentration of the DNA
repair product 8-OHdG has been proposed as a noninvasive biomarker of oxidative DNA
damage in human in vivo. Carvedilol has shown to have antioxidant actions in patients by
reduction of anti-oxidized LDL antibodies and to reduce ROS in normal human subjects.
However, there has been no data that carvedilol reduce DNA damage in human hyper-
tension. Methods: Seventeen newly diagnosed hypertension patients (mean age
=51±11, male/female=11/6) who have not taken antihypertensive medication previously
volunteered for the study. Fasting blood sample were collected at baseline in tubes with
EDTA as an anticoagulant. The subjects were given 12.5 or 25 mg of carvedilol PO once
a day for 2 months. Two months later, another blood sample was collected as above. Age
and sex matched control subjects (n=22, mean age =45±12, male/female=14/8), not
given any drugs, also had 2 samples taken 2 months apart. None of the subjects were on
any medications, including NSAIDs, Vitamin E, or other antioxidants. Serum 8-OHdG
was measured with ELISA method. High sensitivity C-reactive protein (hs-CRP) was also
checked two times. There were no statistical differences in smoking, diabetes, and total
cholesterol level between hypertension and control group. Results: In the hypertension
group, DNA damage biomarker 8-OHdG at baseline was 9.07±4.23 ng/ml (mean±SD).
After carvedilol administration, it fell to 5.74±3.89 ng/ml (p=0.002). In the control group,
the 8-OHdG concentrations were 3.41±2.03, 3.01±2.65 ng/ml at baseline and 2 months
later, respectively (p=NS). The baseline 8-OHdG was higher in the group of hypertension
than in control(p=0.001). hs-CRP had no significant difference before and after carvedilol
treatment in the hypertension group( 0.21±0.51, 0.19±0.37 mg/dl). Conclusion: DNA
damage due to ROS occurs more in hypertension patients than in normal blood pressure
people. Carvedilol may significantly reduce DNA damage in hypertension patients.
1161-177 Modulatory Effect of Inflammation on Blood Pressure 
Reduction Following Therapeutic Lifestyle Change via 
Cardiac Rehabilitation and Exercise Training
Richard V. Milani, Carl J. Lavie, Ochsner Clinic Foundation, New Orleans, LA
Background: Inflammation promotes the development and progression of atherosclerosis
and is associated with several traditional CV risk factors including hypertension, diabe-
tes, and dyslipidemia. We evaluated the impact of inflammation on improvement in risk
factors following 12 weeks (36 sessions) of therapeutic lifestyle change (TLC) via cardiac
rehabilitation and exercise training (CRET) in 635 patients (mean age 64.6 ±10.7 years)
4-6 weeks following a major CHD event.
Methods: Patients were dichotomized based upon baseline median hs-CRP (median =
3.2 mg/L) values. At baseline there were no differences in age, gender, systolic and dias-
Controls (n=59) Hypertensive (n=199) p-value
SBP (mmHg) 130(9) 147(22) 0.001
DBP (mmHg) 80 (9) 80(11) 0.9
s P-selectin (ng/ml) 77(38-110) 150(106-213) <0.001
VEGF (ng/ml) 500(42-7750) 1500(30-100000) <0.001
Ang-1 (ng/ml) 10(6-60) 700(250-1300) <0.001
Ang-2 (ng/ml) 1.8(0.5-3.0) 1.8(1.1-3.5) 0.01
Platelet VEGF (ng/ml) 30 (10-200) 600(50-3000) <0.001
JACC March 3, 2004 ABSTRACTS - Vascular Disease, Hypertension, and Prevention  523A
Vascular Disease, Hypertension, and Prevention
tolic BP, mean arterial pressure (MAP), total cholesterol, HDL, and LDL, between high
and low CRP groups. High CRP patients did however demonstrate higher BMI (+4%;
p=0.02), triglycerides (+13%; p=0.07), %fat (+6%; p=0.01), resting heart rate (+6%;
p=0.004) as well as a lower peak VO2 (-9%; p<0.0001) respectively.
Results: Following CRET, both high and low CRP groups exhibited statistical improve-
ments in %fat (-3.0%, -4.3%), HDL (+7.3%, +7.1%), triglycerides (-12.1%, -8.2%) and
peakVO2 (+11.0%, +8.8%) respectively. Systolic, diastolic and MAP improved in patients
with low CRP but did not change in high CRP patients (Table).
Conclusion: Therapeutic lifestyle change implemented through CRET improves most CV
risk factors. High levels of inflammation, however, appear to blunt the hemodynamic
improvements normally associated with CRET.
1161-178 N-Terminal Pro-Brain Natriuretic Peptide Can Identify 
High and Low Risk Patients With Hypertension and 
Preserved Left Ventricular Systolic Function in the 
General Population
Ilan E. Raymond, Frants Pedersen, Per Rossen Hildebrandt, H:S Frederiksberg Hospital, 
Copenhagen, Denmark
Background: N-terminal pro-Brain Natriuretic Peptide (NT-proBNP) has shown promis-
ing ability to identify subjects with cardiovascular diseases (CV) including hypertension.
The purpose of the study was to evaluate NT-proBNP as a marker of high-risk patients
with hypertension and preserved left ventricular systolic function (LVSF) in the general
population.
Methods: A total of 683 unselected subjects (383 women and 300 men) older than 50
years (mean age 68 + 11 years, range: 50-89 years) from randomly selected general
practitioners filled in a heart failure questionnaire, had an ECG recorded, echocardio-
graphy performed and blood samples taken, and blood pressure and heart rate were
measured. Hypertension was history of hypertension or blood pressure exceeding 150/
90. Preserved LVSF was LVEF<0.50.
Results: 316 subjects fulfilled the criteria of hypertension. Median (range) follow-up was
1145 (51-1197) days, 25 deaths were registered. In a Cox proportional hazards analyses
age, sex, LVEF, systolic and diastolic blood pressures, logNT-proBNP were evaluated as
potential prognostic factors for mortality. LogNT-proBNP (hazard ratio (HR)=8.4,
p<0.0001) and male sex (HR=3.2, p=0.007) was independent markers for mortality. In a
Cox proportional hazards analyses subjects with NT-proBNP above median value (= 33
pmol/l) including the same variables, NT-proBNP (HR=3.3, p=0.045), male sex (HR=2.9,
p=0.01) and age (HR=1.05 per year, p=0.05) were independent markers for mortality.
When raising the cut of value of NT-proBNP with 5% in the analyses, only logNT-proBNP
was a significant predictor of mortality (p<0,0001), independent of age and sex.
Conclusion: In this large sample of the general population, NT-proBNP was a strong
predictor of death within the population suffering from hypertension..
1161-179 Serum Uric Acid and Risk for Development of 
Hypertension: The Normative Aging Study
Todd S. Perlstein, David Sparrow, Scott T. Weiss, Gordon H. Williams, Augusto A. 
Litonjua, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background:Experimental and epidemiological data suggest that uric acid might have a
role in the pathogenesis of hypertension. We sought to examine if uric acid predicts the
risk of developing hypertension in a group of normotensive adult males.
Methods: The Normative Aging Study, established in 1961, is an ongoing longitudinal
cohort of 2280 males initially free of chronic medical disorders such as hypertension.
Comprehensive medical and laboratory evaluations are performed every three to five
years. We used multivariate Cox proportional hazards analysis to determine independent
risk factors for the development of hypertension. Variables considered were serum uric
acid (SUA) level, age, body mass index (BMI), alcohol intake, smoking status, fasting
plasma glucose, total cholesterol, and serum triglycerides. Hypertension was defined as
the examining study physician having recorded a diagnosis of hypertension and either a
blood pressure of greater than 140/90 mm Hg or treatment with anti-hypertensive medi-
cations.
Results: At baseline, the study population had a mean age of 42 ± 9 years, a mean BMI
of 25.6 ± 2.8 kg/m2, and a mean SUA level of 5.8 ± 0.9 mg/dL. In univariate analysis,
SUA level was associated with a risk ratio for hypertension of 1.12 (p = 0.002). Other
univariate predictors were age, BMI, total cholesterol and serum triglycerides. In multi-
variate analyses, SUA level was independently associated with the risk of hypertension
(RR = 1.10, p = 0.03). Other independent predictors were age (p = 0.0001) and BMI (p =
0.0001).
Conclusion: Uric acid level independently predicted the risk of hypertension in this longi-
tudinal cohort of healthy adult males. These data add to the evidence that uric acid might
have a causal role in the development of hypertension.
1161-180 Which Is the Best Pharmacological Treatment for Obese 
Hypertensive Patients With Hyperuricemia?
Kazuko Masuo, Hiroshi Mikami, Toshio Ogihara, Michael L. Tuck, Osaka University 
Graduate School of Medicine, Suita City, Osaka, Japan, Sepulveda VA Medical Center, 
Sepulveda, CA
Background: It is well-known than obesity and elevated serum uric acid (UA) are risk fac-
tors for cardiovascular diseases, and that weight loss (WL) program is an essential com-
ponent for obesity-hypertension. To know the best way for reducing BP and UA levels in
obese, hyperuricemic, hypertensive (HT) patients, we conducted this study. Methods: 6
groups with 20 obese HT men each were measured BMI, BP, UA, plasma norepinephrine
(NE), insulin and leptin at entry and 12 months. The 6 study groups were matched in age,
BMI, BP and UA at entry. All subjects had hyperUA (>6.5 mg/dL) and non-diabetes
(HbA1c<6.0%). As a significant WL was defined as more than 10% decrease in BMI at
12 months from entry, success rates were 50%** in WL alone, 40%* in ARB+WL, 40%* in
ACEI+WL, 25% in CCB+WL, 15% in alpha+WL, and 10% in beta+WL (*P<.05, **P<.01
vs beta+WL). UA at 12 months were greater in beta+WL > CCB+WL > alpha+WL > WLa-
lone > ACEI+WL > ARB+WL (7.4 mg/dL, 6.8, 6.5*, 6.1**, 5.8**, 5.3**). BP levels at 12
months in pharmacological Tx with failure in WL were lower than in WL alone, and higher
than in pharmacological Tx with success in WL, although BP were similar among the 5
pharmacological Tx groups. Decreases in BMI were greater in WL alone > ARB+WL
>ACEI+WL > CCB+WL > alpha+WL = beta+WL. Decreases in NE were greater in
ARB+WL > ACEI+WL > beta+WL > WL alone > alpha+WL > CCB+WL. Decreases in
insulin were greater in ARB+WL > ACEI+WL > alpha+WL > WL alone > CCB+WL >
beta+WL. Leptin decreased only in subjects with a significant WL. Changes in NE corre-
lated with changes in UA and with changes in mean BP. Changes in insulin correlated
with changes in UA. Conclusions: These results demonstrate that beta- & alpha-blockers
and CCB groups appear to be more resistant to WL and reducing hyperUA compared
with ARB, ACEI or WL alone groups, suggesting that ARB or ACEI should be taken as
the first choice for obesity hypertension with hyperuricemia. WL is an effective treatment
for obesity hypertension with hyperuricemia. Suppression of sympathetic overactivity and
hyperinsulinemia appears to be major roles in the mechanisms of lowering serum UA in
obese hypertensives.
1161-181 Regular Exercise Improves Risk Profile and Motor 
Development in Early Childhood
Kerstin S. Ketelhut, Iman Mohasseb, Christiane Scheffler, Reinhard G. Ketelhut, 
Universität Potsdam, Berlin, Germany, Humboldt-Universität, Berlin, Germany
Even in young children a weakened motor development paralleled by impaired cardiovas-
cular risk profile can be obeserved in industrialized countries. Therefore 3year old chil-
dren were included in a prospective, controlled 2-year intervention study to assess the
efficacy of a regular exercise program (3x a week) on blood pressure (BP), heart rate
(HR), body mass index (BMI) and motor skills.
Methods: 160 children out of a total of 265 (aged 3.5 years) in 17 nursery schools in
Germany participated in a regular exercise program. 105 comparable subjects served as
controls. BP and HR were evaluated at rest by standardized procedures. BMI was calcu-
lated by body-weight and hight. Standardized motor testing included jumping, running,
balance and coordination skills.
Results: Before intervention there were no significant differences between the groups in
all measurements and tests. So far, after one year of intervention, no difference could be
observed in BMI between interventions (I) and controls (C). In contrast, HR which is
known to decrease with age, decreased more in I (7.4%) than in C (5.8%) (p<0.05). This
was true for diastolic BP as well with a tendency towards lower systolic BP, respectively.
Furthermore, the intervention group came off better in all motor tests, with significant dif-
ferences (p<0.001) in such as balance (180cm vs. 130cm) and coordination tests (23.2
points vs.16.7 points).
Conclusion: The study provides evidence that regular exercise improves motor develop-
ment in early childhood due to one year of regular exercise. Moreover, these findings are
paralleled by positive influence on cardiovascular risk factors such as BP and HR. There-
fore, regular physical exercise should be started in early childhood before the first health
deficits and risk profile become evident.
1161-182 Treatment Patterns for Hypertension, Dyslipidaemia, 
and Both Conditions in the United Kingdom: 1997 to 
2001
T. M. MacDonald, S. V. Morant, Christine Baker, Essy Mozaffari, University of Dundee, 
Dundee, United Kingdom
Background: Little is known about the incidence and treatment rates of hypertension
(HTN), dyslipidaemia (DYS), and particularly concomitant HTN/DYS in the United King-
dom (UK). This study was therefore undertaken to measure the annual incidence rates of
recorded, diagnosed, and treated HTN, DYS, and HTN/DYS in a primary care setting.
Methods: This was a retrospective cohort study using the General Practice Research
Database. A fixed population of 399,933 patients aged >40 years, present throughout (or
died during) 1997 to 2001, and who had a minimum 1-year, lead-in history were studied.
Incident HTN patients had not previously been treated or met the criteria for HTN (sys-
tolic blood pressure [BP] >140 mmHg) prior to January 1 each year but had BP recorded
as >140/90 mmHg, subsequently. Similar analyses for incident DYS (total cholesterol >5
mmol/L or low-density lipoprotein [LDL] cholesterol >3 mmol/L) and concomitant HTN/
DYS were performed. Incident treatment was defined as newly treated patients each
year. Logistic regression was used to model trends in the incidence rates.
Results: Between 1997 and 2001, incident DYS diagnoses rose from 1.2% to 3.6%
(+30% per annum [pa]). Incident HTN diagnoses fell from 2.0% to 1.1% (-14% pa), but
concurrent HTN/DYS rose from 0.8% to 2.0% (+27% pa). Incident DYS drug treatment
rose from 0.8% to 1.8% (+22% pa). Treatment for HTN rose from 2.4% to 2.9% (+5% pa),
Low CRP High CRP
Systolic Diastolic MAP Systolic Diastolic MAP
Pre 139±20 76±14 97±14 136±19 74±12 95±12
Post 134±19 73±13 93±13 136±18 74±13 95±12
% change -3.6% -3.9% -4.1% 0% 0% 0%
p value <0.0001 0.005 <0.0001 ns ns ns
